BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to MIA-PaCa-2 cell line is 377
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BMI1 | 1066 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Transcriptomics and RT-PCR and Western Blotting | Up | 0.52 | 0.1135 | 24719318 |
| FOLR1 | 3791 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Transcriptomics and RT-PCR and Western Blotting | Up | 0.52 | 0.0053 | 24719318 |
| FOXQ1 | 20951 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Transcriptomics and RT-PCR and Western Blotting | Up | 0.52 | 0.0021 | 24719318 |
| BMI1 | 1066 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.1135 | 26840266 |
| HSF1 | 5224 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0032 | 35158144 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.5461 | 34168259 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 35158144 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.5461 | 32575925 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA and Western Blotting | NA | 0.48 | 0.5461 | 35428310 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 26458814 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 30341797 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 30341797 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | Western Blotting | NA | 0.48 | 0.5461 | 29179494 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | qRT-PCR | NA | 0.48 | 0.5461 | 23073476 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by CFA and qRT-PCR | NA | 0.48 | 0.5461 | 24719318 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 24734907 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 26840266 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by FACs | NA | 0.48 | 0.5461 | 29719602 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 35158144 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.6448 | 32575925 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA and Western Blotting | NA | 0.48 | 0.6448 | 35428310 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | CFA followed by Western Blotting | NA | 0.48 | 0.6448 | 25015789 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 30341797 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 30341797 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | Western Blotting | NA | 0.48 | 0.6448 | 29179494 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.6448 | 28490735 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qPCR | NA | 0.48 | 0.6448 | 34168259 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | qRT-PCR | NA | 0.48 | 0.6448 | 23073476 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by CFA and qRT-PCR | NA | 0.48 | 0.6448 | 24719318 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 24734907 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 26840266 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by FACs | NA | 0.48 | 0.6448 | 29719602 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.5695 | 34168259 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 35158144 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.5695 | 32575925 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA and Western Blotting | NA | 0.48 | 0.5695 | 35428310 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | CFA followed by Western Blotting | NA | 0.48 | 0.5695 | 25015789 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 26458814 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 30341797 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 30341797 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | Western Blotting | NA | 0.48 | 0.5695 | 29179494 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 24734907 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 26840266 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by FACs | NA | 0.48 | 0.5695 | 29719602 |
| EZH2 | 3527 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by RT-PCR and IHC staining | NA | 0.44 | 0.0074 | 24734907 |
| EZH2 | 3527 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by CFA and IF staining | NA | 0.44 | 0.0074 | 24719318 |
| ALDH1A1 | 402 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.4 | 0.684 | 34168259 |
| CD44 | 1681 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.4 | 1 | 34168259 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by ALDEFLUOR assay and Western Blotting | NA | 0.4 | 0.684 | 20940707 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by ALDEFLUOR assay and qRT-PCR | NA | 0.4 | 0.684 | 33110235 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | ALDEFLUOR assay followed by qRT-PCR | NA | 0.4 | 0.684 | 23073476 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA and Western Blotting | NA | 0.4 | 0.684 | 35428310 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | CFA followed by Western Blotting | NA | 0.4 | 0.684 | 25015789 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Western Blotting | NA | 0.4 | 0.684 | 26458814 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | Western Blotting | NA | 0.4 | 0.684 | 24676703 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | Western Blotting | NA | 0.4 | 0.684 | 31106493 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | Western Blotting | NA | 0.4 | 0.684 | 29179494 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | Western Blotting followed by SFA | NA | 0.4 | 0.684 | 28490735 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA and CFA followed by ALDEFLUOR assay and FACs | NA | 0.4 | 0.684 | 20940707 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | ALDEFLUOR assay followed by CFA | NA | 0.4 | 0.684 | 32550888 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | ALDEFLUOR assay | NA | 0.4 | 0.684 | 31312365 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | ALDEFLUOR assay | NA | 0.4 | 0.684 | 24194908 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by SFA | NA | 0.4 | 0.684 | 27999190 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by ALDEFLUOR assay | NA | 0.4 | 0.684 | 20664924 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by FACs and Western Blotting | NA | 0.4 | 0.456 | 27432228 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | Western Blotting followed by FACs | NA | 0.4 | 0.456 | 28775772 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | Western Blotting followed by FACs and SFA | NA | 0.4 | 0.456 | 29179494 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by IHC staining and SFA | NA | 0.4 | 0.456 | 31510100 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by SP assay and Western Blotting | NA | 0.4 | 0.456 | 23864708 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Western Blotting | NA | 0.4 | 0.456 | 26673007 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | qRT-PCR | NA | 0.4 | 0.456 | 24726912 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qRT-PCR | NA | 0.4 | 0.456 | 26840266 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by FACs | NA | 0.4 | 0.456 | 34123574 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Cisplatin | SFA followed by FACs and Imaging FACs | NA | 0.4 | 0.456 | 34123574 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs | NA | 0.4 | 0.456 | 22948659 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs | NA | 0.4 | 0.456 | 26546043 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs and CFA followed by SFA and Tumorigenicity assay | NA | 0.4 | 0.456 | 23017870 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by SFA | NA | 0.4 | 0.456 | 27999190 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by Tumorigenicity assay | NA | 0.4 | 0.456 | 20940707 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by FACs | NA | 0.4 | 0.456 | 29719602 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Triptolide | SP assay followed by FACs | NA | 0.4 | 0.456 | 26597727 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by FACs and Western Blotting | NA | 0.4 | 1 | 27432228 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | Western Blotting followed by FACs and SFA | NA | 0.4 | 1 | 29179494 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by IHC staining and SFA | NA | 0.4 | 1 | 31510100 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | IF staining followed by FACs | NA | 0.4 | 1 | 19714243 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | IF staining followed by FACs | NA | 0.4 | 1 | 19714243 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA and Western Blotting | NA | 0.4 | 1 | 35428310 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by SP assay and Western Blotting | NA | 0.4 | 1 | 23864708 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Western Blotting | NA | 0.4 | 1 | 26458814 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Western Blotting | NA | 0.4 | 1 | 26673007 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | Western Blotting | NA | 0.4 | 1 | 31106493 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | Western Blotting followed by SFA | NA | 0.4 | 1 | 28490735 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | IF staining followed by SFA | NA | 0.4 | 1 | 29107110 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by CFA and IF staining | NA | 0.4 | 1 | 24719318 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | qRT-PCR | NA | 0.4 | 1 | 23073476 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | qRT-PCR | NA | 0.4 | 1 | 24726912 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qRT-PCR | NA | 0.4 | 1 | 26840266 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by FACs | NA | 0.4 | 1 | 34123574 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Cisplatin | SFA followed by FACs and Imaging FACs | NA | 0.4 | 1 | 34123574 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs | NA | 0.4 | 1 | 22948659 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs | NA | 0.4 | 1 | 26302089 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs | NA | 0.4 | 1 | 26546043 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs and CFA followed by SFA and Tumorigenicity assay | NA | 0.4 | 1 | 23017870 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by SFA | NA | 0.4 | 1 | 24719318 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by SFA | NA | 0.4 | 1 | 32575925 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by SFA | NA | 0.4 | 1 | 27999190 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by SFA and Migration assay | NA | 0.4 | 1 | 24734907 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by Tumorigenicity assay | NA | 0.4 | 1 | 22111082 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by Tumorigenicity assay | NA | 0.4 | 1 | 20940707 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by CFA and FACs | NA | 0.4 | 1 | 20940707 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by FACs | NA | 0.4 | 1 | 29719602 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Triptolide | SP assay followed by FACs | NA | 0.4 | 1 | 26597727 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by FACs and Western Blotting | NA | 0.4 | 0.211 | 27432228 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | Western Blotting followed by FACs | NA | 0.4 | 0.211 | 28775772 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by IHC staining and SFA | NA | 0.4 | 0.211 | 31510100 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Western Blotting | NA | 0.4 | 0.211 | 26673007 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | Western Blotting | NA | 0.4 | 0.211 | 31106493 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by CFA and IF staining | NA | 0.4 | 0.211 | 24719318 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qRT-PCR | NA | 0.4 | 0.211 | 26840266 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Cisplatin | SFA followed by FACs | NA | 0.4 | 0.211 | 34123574 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by FACs | NA | 0.4 | 0.211 | 34123574 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs | NA | 0.4 | 0.211 | 22948659 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs | NA | 0.4 | 0.211 | 26302089 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs | NA | 0.4 | 0.211 | 26546043 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by SFA | NA | 0.4 | 0.211 | 24719318 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by SFA | NA | 0.4 | 0.211 | 27999190 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by SFA and Migration assay | NA | 0.4 | 0.211 | 24734907 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by CFA and FACs | NA | 0.4 | 0.211 | 20940707 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by FACs | NA | 0.4 | 0.211 | 29719602 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Triptolide | SP assay followed by FACs | NA | 0.4 | 0.211 | 26597727 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | Western Blotting followed by FACs and SFA | NA | 0.4 | 0.7582 | 29179494 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | IF staining followed by FACs | NA | 0.4 | 0.7582 | 19714243 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | IF staining followed by FACs | NA | 0.4 | 0.7582 | 19714243 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by SFA and qPCR | NA | 0.4 | 0.7582 | 32575925 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Western Blotting | NA | 0.4 | 0.7582 | 26317547 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Western Blotting | NA | 0.4 | 0.7582 | 26458814 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | MACs followed by FACs and SFA | NA | 0.4 | 0.7582 | 25551472 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qRT-PCR | NA | 0.4 | 0.7582 | 33110235 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | qRT-PCR | NA | 0.4 | 0.7582 | 24726912 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs | NA | 0.4 | 0.7582 | 22948659 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs | NA | 0.4 | 0.7582 | 26302089 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by SFA | NA | 0.4 | 0.7582 | 24719318 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | FACs followed by SFA and Migration assay | NA | 0.4 | 0.7582 | 24734907 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by CFA and FACs | NA | 0.4 | 0.7582 | 20940707 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Triptolide | SP assay followed by FACs | NA | 0.4 | 0.7582 | 26597727 |
| HNRNPAB | 5034 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.36 | 0.0032 | 34168259 |
| LDHA | 6535 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.36 | 0.0053 | 34168259 |
| VDAC2 | 12672 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.36 | 0.0011 | 34168259 |
| HDHA | NA | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0011 | 34168259 |
| HNRNPAB | 5034 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics and Western Blotting | Down | 0.36 | 0.0032 | 34168259 |
| LDHA | 6535 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics and Western Blotting | Down | 0.36 | 0.0053 | 34168259 |
| VDAC2 | 12672 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0011 | 34168259 |
| MIR744 | 33658 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qRT-PCR and FACs and Tumorigenicity assay | NA | 0.32 | 0.0021 | 26485754 |
| DCLK1 | 1681 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by FACs | NA | 0.28 | 0.0159 | 26673007 |
| DCLK1 | 2700 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0159 | 26317547 |
| NOTCH1 | 7881 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | CFA followed by Western Blotting | NA | 0.28 | 0.0477 | 25015789 |
| NOTCH1 | 7881 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0477 | 20940707 |
| NOTCH1 | 7881 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by CFA and IF staining | NA | 0.28 | 0.0477 | 24719318 |
| NOTCH1 | 7881 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by RT-PCR | NA | 0.28 | 0.0477 | 24734907 |
| PAK4 | 16059 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | Western Blotting | NA | 0.28 | 0.0011 | 26546043 |
| BMP4 | 1071 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0021 | 24719318 |
| BST2 | 1119 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0032 | 24719318 |
| BTG1 | 1130 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0011 | 24719318 |
| MIR125B1 | 31506 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 24734907 |
| MIR30A | 31624 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0085 | 24734907 |
| MIR30C1 | 31626 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0042 | 24734907 |
| MIR335 | 31773 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 24734907 |
| MIRLET7F1 | 31483 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0053 | 24734907 |
| MIRLET7FI | 31483 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 24734907 |
| PRKAR1A | 9388 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0011 | 24719318 |
| SOX4 | 11200 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0042 | 24719318 |
| TACSTD2 | 11530 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0042 | 24719318 |
| WNT3A | 15983 | HTM/LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0021 | 24719318 |
| SNAI1 | 11128 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by CFA and IF staining | NA | 0.24 | 0.0212 | 24719318 |
| ABCB1 | 40 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0604 | 33110235 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.1739 | 33110235 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | qRT-PCR | NA | 0.2 | 0.1739 | 23073476 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Cisplatin | SFA followed by FACs | NA | 0.2 | 0.1739 | 34123574 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by FACs | NA | 0.2 | 0.1739 | 34123574 |
| AKT1 | 391 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by CFA and qRT-PCR | NA | 0.2 | 0.0074 | 24719318 |
| AKT1 | 391 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0074 | 24734907 |
| CCNB1 | 1579 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qPCR | NA | 0.2 | 0.0053 | 34168259 |
| FZD2 | 4040 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qPCR | NA | 0.2 | 0.0021 | 34168259 |
| HIF1A | 4910 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by CFA and qRT-PCR | NA | 0.2 | 0.0106 | 24719318 |
| HSPA6 | 5239 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by qRT-PCR | NA | 0.2 | 0.0053 | 35158144 |
| HSPE1 | 5269 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by qRT-PCR | NA | 0.2 | 0.0053 | 35158144 |
| HSPH1 | 16969 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by qRT-PCR | NA | 0.2 | 0.0021 | 35158144 |
| IGF1 | 5464 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by CFA and qRT-PCR | NA | 0.2 | 0.0053 | 24719318 |
| IL6 | 6018 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by CFA and qRT-PCR | NA | 0.2 | 0.0191 | 24719318 |
| LGR5 | 4504 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0753 | 26840266 |
| MYC | 7553 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.1304 | 26840266 |
| VEGF | 12680 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by CFA and qRT-PCR | NA | 0.2 | 0.0042 | 24719318 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by CFA and FACs | NA | 0.12 | 0.456 | 20940707 |
| CXCR4 | 2561 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by CFA and FACs | NA | 0.12 | 0.0498 | 20940707 |
| ERBB2 | 3430 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Gemcitabine | SFA followed by FACs and Imaging FACs | NA | 0.12 | 0.0074 | 34123574 |
| ERBB2 | 3430 | LTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | Cisplatin | SFA followed by FACs and Imaging FACs | NA | 0.12 | 0.0074 | 34123574 |
| AARS1 | 20 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| ABHD11 | 16407 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| ACAA2 | 83 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| ACADVL | 92 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| ACAT1 | 93 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| ACO2 | 118 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| ACOT13 | 20999 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| ACOT7 | 24157 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| ACTC1 | 143 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| ACTN4 | 166 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0074 | 34168259 |
| AFG3L2 | 315 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| AHNAK | 347 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| AIFM1 | 8768 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| ALB | 399 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| ALDH7A1 | 877 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| ALDOA | 414 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| ANXA2 | 537 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| APRT | 626 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| ARF4 | 655 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| ATAD3A | 25567 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| ATP5F1A | 823 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| ATP5F1B | 830 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| ATP5F1C | 833 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| ATP5F1D | 837 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| ATP5MC1 | 841 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| ATP5PB | 840 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| ATP5PD | 845 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| ATP5PO | 850 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| C1QBP | 1243 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| CACYBP | 30423 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| CALR | 1455 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| CANX | 1473 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| CAPG | 1474 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| CAPRIN1 | 6743 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| CBR1 | 1548 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| CCT2 | 1615 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| CCT4 | 1617 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| CCT7 | 1622 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| CRAT | 2342 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| CS | 2422 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| CYB5B | 24374 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| CYC1 | 2579 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| DDX21 | 2744 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| DHCR24 | 2859 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 34168259 |
| DHRS7 | 21524 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| DLD | 2898 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| DLST | 2911 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| DNAJB6 | 14888 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| ECH1 | 3149 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| ECHS1 | 3151 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| EEF1A2 | 3192 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| EEF1D | 3211 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| EIF2S1 | 3265 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| EIF2S3B | 43863 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| EIF5A | 3300 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| ELAVL1 | 3312 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| ENO1 | 3350 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0095 | 34168259 |
| ENO2 | 3353 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| ERP29 | 13799 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| ESYT2 | 22211 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| ETFA | 3481 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| EZR | 12691 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0064 | 34168259 |
| FASN | 3594 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0074 | 34168259 |
| FAU | 3597 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| FDPS | 3631 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| FLNA | 3754 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| GAPDH | 4141 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 34168259 |
| GDI2 | 4227 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| GLUD1 | 4335 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| GOT2 | 4433 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| GPI | 4458 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| GSN | 4620 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 34168259 |
| GSTP1 | 4638 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 34168259 |
| H1-0 | 4714 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| H1-3 | 4717 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| H1-5 | 4719 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| H2AC21 | 20508 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| H3C1 | 4774 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| HADHA | 4801 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| HADHB | 4803 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| HBA1 | 4823 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| HBB | 4827 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| HEXB | 4879 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| HK1 | 4922 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| HMGA1 | 5010 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| HPCAL1 | 5145 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| HSD17B10 | 4800 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| HSP90AA1 | 5253 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0064 | 34168259 |
| HSP90AB1 | 5258 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0074 | 34168259 |
| HSP90B1 | 12028 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| HSPA4 | 5237 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| HSPA5 | 5238 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0117 | 34168259 |
| HSPA8 | 5241 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0085 | 34168259 |
| HSPA9 | 5244 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| HSPD1 | 5261 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0064 | 34168259 |
| HYOU1 | 16931 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| IMMT | 6047 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| ISG15 | 4053 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| KRT10 | 6413 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| KRT18 | 6430 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0074 | 34168259 |
| KRT19 | 6436 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0074 | 34168259 |
| KRT2 | 6439 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| KRT79 | 28930 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| KRT8 | 6446 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0074 | 34168259 |
| LAMP2 | 6501 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| LONP1 | 9479 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| LRPPRC | 15714 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0064 | 34168259 |
| LRRC59 | 28817 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| MATR3 | 6912 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| MDH2 | 6971 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| MOGS | 24862 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| MTCH2 | 17587 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| NAP1L1 | 7637 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| NDUFS3 | 7710 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| NME2 | 7850 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| NPM1 | 7910 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| NQO1 | 2874 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| PAICS | 8587 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| PCK2 | 8725 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| PDHB | 8808 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| PDIA3 | 4606 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| PDIA4 | 30167 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 34168259 |
| PDIA6 | 30168 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| PGK1 | 8896 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| PHB | 8912 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| PHB2 | 30306 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| PPIB | 9255 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| PPP1CB | 9282 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| PRDX3 | 9354 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| PRDX5 | 9355 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| PRKCSH | 9411 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| PSAP | 9498 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| PYGB | 9723 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RAB7A | 9788 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| RBBP7 | 9890 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| RPL12 | 10302 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| RPL13 | 10303 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| RPL26 | 10327 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| RPL27 | 10328 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| RPL29 | 10331 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| RPL4 | 10353 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| RPL7A | 10364 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| RPL8 | 10368 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| RPN2 | 10382 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| RPS11 | 10384 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| RPS13 | 10386 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| RPS14 | 10387 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| RPS16 | 10396 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| RPS19 | 10402 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| RPS23 | 10410 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| RPS25 | 10413 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| RPS7 | 10440 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| SARS1 | 10537 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| SF3B3 | 10770 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| SFXN1 | 16085 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| SH3BGRL3 | 15568 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| SHMT2 | 10852 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| SLC25A1 | 10979 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| SLC25A10 | 10980 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| SLC25A3 | 10989 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| SLC25A5 | 10991 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| SLC25A6 | 10992 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| SNRPD1 | 11158 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0011 | 34168259 |
| SSBP1 | 11317 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| SSR1 | 11323 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| STIP1 | 11387 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0042 | 34168259 |
| STMN1 | 6510 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| STOML2 | 14559 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| TFRC | 11763 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0053 | 34168259 |
| TGM2 | 11778 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| TMEM109 | 28771 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| TMPO | 11875 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| TMSB4X | 11881 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| TPM3 | 12012 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0021 | 34168259 |
| TUFM | 12420 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34168259 |
| UQCRC1 | 12585 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34168259 |
| USP5 | 12628 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| VDAC1 | 12669 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34168259 |
| VTN | 12724 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34168259 |
| XRCC5 | 12833 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |
| YWHAB | 12849 | HTM | Pancreatic Cancer | Carcinoma | MIA-PaCa-2 | NA | SFA followed by Proteomics | Down | 0.08 | 0.0032 | 34168259 |